Oruka Therapeutics, Inc. (ORKA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$92.51+1.67%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ORKA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress clinical trials of ORKA-001 including Phase 2a, Phase 2b, and planned Phase 3 to establish efficacy and support BLA filing.
Stated as a priority in 3 distinct disclosures including 2026-Q2. Management reported positive Phase 2a data with 63.5% PASI 100 at Week 16, full enrollment of 187 subjects in Phase 2b EVERLAST-B, and plans to start Phase 3 in 1H 2027. Cash position of $1.1 billion at 2026-Q2 supports funding through BLA filing. The trajectory is delivering with advancing clinical milestones and sufficient capital.
“Phase 3 program for ORKA-001 expected to begin in 1H 2027; EVERLAST-B fully enrolled; Week 28 and 52-week data expected in 3Q and December 2026.”
“Advancing clinical development of ORKA-001 with ongoing trials and data milestones.”
Advance ORKA-002 through Phase 2 trials in psoriasis and hidradenitis suppurativa, including ORCA-SURGE and ORCA-SPLASH studies.
Stated in 2 quarters including 2026-Q2. Management initiated the ORCA-SPLASH Phase 2 trial enrolling about 160 patients and expects ORCA-SURGE data in early 2027. These steps show progress in expanding ORKA-002 clinical development into hidradenitis suppurativa and psoriasis. The trajectory is delivering with trial initiation and enrollment underway.
“Initiated ORCA-SPLASH Phase 2 trial in hidradenitis suppurativa; ORCA-SURGE Week 16 data expected in 1Q 2027.”
“Advancing ORKA-002 development with ongoing Phase 2 trials in psoriasis and hidradenitis suppurativa.”
Manage cash and capital resources to support clinical development and regulatory milestones through anticipated BLA filing for ORKA-001.
Stated in 2 quarters including 2026-Q2. Cash and equivalents rose from about $496 million in 2026-Q1 to $1.1 billion in 2026-Q2, reflecting capital raises. Management expects this capital to fund operations through the anticipated BLA filing for ORKA-001. The trajectory is delivering with strong cash position supporting development plans.
“Cash, cash equivalents, and marketable securities of $1.1 billion expected to fund operations through BLA filing for ORKA-001.”
“Preliminary cash and investments estimated at approximately $496 million as of March 31, 2026.”
Focus on controlling operating losses and cash flow from operations amid ongoing development activities.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Over the trailing year it converted 0.84x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
12 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.